Exclusive Summary

• Perfluoropropane-Albumin Microspheres for Injection is a core ultrasound contrast agent (UCA) used in echocardiography enhancement, addressing a stable and growing global diagnostic imaging market estimated at USD 7–9 billion in 2023 with ~6–8% CAGR through 2030.
• The original patent for Optison (GE Healthcare) has largely expired in most markets, opening registration pathways for biosimilar/generic UCAs, particularly in emerging markets where regulatory flexibility is higher.
• Chinese-manufactured product offers a 30–60% cost advantage over originator products priced at USD 200–300/vial in the US/EU, making it highly competitive for price-sensitive markets in Southeast Asia, Middle East, Latin America, and Africa.
• All markets are open for distribution partnership, with particular fit for emerging market partners who have established hospital/diagnostic imaging distribution networks and can leverage NMPA approval as a registration reference.
• Clinical demand is structurally driven: globally over 100 million echocardiograms are performed annually, with 10–15% requiring contrast enhancement, representing a rigid and recurring demand base of approximately 10–15 million potential patients per year.